SuChun

Suchun Biopharma is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary Su-Link platform, which employs site-specific conjugation technology to produce ADCs with superior stability, homogeneity, and an expanded therapeutic window compared to traditional methods. Its lead asset, SC-001, is a Claudin 18.2-targeted ADC currently in Phase 1 clinical trials for advanced solid tumors, including gastric and pancreatic cancers. Suchun's pipeline also features several preclinical programs targeting well-validated oncology receptors such as TROP2 and Nectin-4. Led by industry veterans with deep expertise in biologics, the company aims to provide more effective and safer therapeutic options for cancer patients globally.